Pasithea Therapeutics Completes Patient Enrollment for PAS-004 Trial
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has made significant strides in its Phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor designed for treating advanced cancer. Recently, the company announced the successful completion of enrollment and initial dosing for patients in Cohort 6, marking a pivotal moment in their research journey.
Rapid Recruitment and Future Expectations
Dr. Tiago Reis Marques, the Chief Executive Officer of Pasithea, expressed enthusiasm as they quickly enrolled and began dosing the initial three subjects in Cohort 6. This swift progress was faster than anticipated, and Pasithea aims to fully enroll all patients involved in the trial by the end of the year, signaling a promising timeline for the research.
Understanding the Phase 1 Clinical Trial
The ongoing Phase 1 clinical trial is distinguished by its multi-center and open-label design, utilizing a dose escalation 3+3 study model. This structure is crucial for evaluating the safety and tolerability of PAS-004. The primary focus targets advanced solid tumors characterized by specific mutations, notably in the MAPK pathway, which includes RAS, NF1, or RAF mutations. Additionally, it is suitable for patients who have not responded to previous BRAF/MEK inhibition treatments.
Key Features of PAS-004
PAS-004 represents a cutting-edge approach to cancer treatment, particularly relevant to those with neurofibromatosis type 1 (NF1) and other conditions driven by the MAPK pathway. By specifically addressing these pathways, Pasithea aims to enhance therapeutic outcomes for patients with challenging diagnoses.
Company Overview and Future Directions
Pasithea is dedicated to innovating in the biomedical field, focusing on CNS disorders and MAPK pathway-driven tumors. Their commitment to research and development charters a path toward novel therapeutic solutions that not only aim for efficacy but also strive for safety and tolerability.
Contact Information
For further inquiries, Patrick Gaynes of Corporate Communications at Pasithea can be reached via email at pgaynes@pasithea.com. Share your questions or requests for additional information as the company forges ahead with its promising clinical studies.
Frequently Asked Questions
What is PAS-004?
PAS-004 is a next-generation macrocyclic MEK inhibitor being developed by Pasithea Therapeutics for the treatment of advanced cancer.
What does the Phase 1 trial entail?
The Phase 1 trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PAS-004 in patients with specific genetic mutations related to MAPK pathway-driven tumors.
Who is eligible for the trial?
Patients with documented RAS, NF1, or RAF mutations, as well as those who have failed previous BRAF/MEK inhibition therapies, are eligible for participation in this trial.
What are the future plans for PAS-004?
Pasithea aims to complete enrollment for the trial by the end of the year and is looking ahead to expand their research into other related conditions as data becomes available.
How does Pasithea Therapeutics position itself in the biotech industry?
Pasithea focuses on developing innovative treatments for CNS disorders and cancers, leveraging advanced research and a robust pipeline to meet pressing medical needs.
